Shopping Cart
- Remove All
- Your shopping cart is currently empty
AS1810722, a fused bicyclic pyrimidine derivative, is an orally active and potent inhibitor of STAT6, demonstrating an IC50 of 1.9 nM. It exhibits effective inhibition of CYP3A4, positioning it as a promising candidate for research into allergic diseases, including asthma and atopic conditions.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $106 | In Stock | |
5 mg | $247 | In Stock | |
10 mg | $372 | In Stock | |
25 mg | $633 | In Stock | |
50 mg | $892 | In Stock | |
1 mL x 10 mM (in DMSO) | $259 | In Stock |
Description | AS1810722, a fused bicyclic pyrimidine derivative, is an orally active and potent inhibitor of STAT6, demonstrating an IC50 of 1.9 nM. It exhibits effective inhibition of CYP3A4, positioning it as a promising candidate for research into allergic diseases, including asthma and atopic conditions. |
Targets&IC50 | STAT6:1.9 nM |
In vitro | AS1810722 showed potent STAT6 inhibition and a good CYP3A4 inhibition profile.?AS1810722 also inhibited in vitro Th2 differentiation without affecting type 1 helper T (Th1) cell differentiation and eosinophil infiltration in an antigen-induced mouse asthmatic model after oral administration. |
Molecular Weight | 477.51 |
Formula | C25H25F2N7O |
Cas No. | 909561-15-5 |
Smiles | NC(=O)CN1CCN(CC1)c1ccc(Nc2ncc3ccn(Cc4cc(F)cc(F)c4)c3n2)cc1 |
Relative Density. | 1.41 g/cm3 (Predicted) |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
Solubility Information | DMSO: 62.5 mg/mL (130.89 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.